Switzer M E, McKee P A
J Clin Invest. 1976 Apr;57(4):925-37. doi: 10.1172/JCI108369.
When purified antihemophilic factor (Factor VIII) was rechromatographed on 4% agarose in 0.15 M NaCl or 1.0 M NaCl, a single protein peak, containing both procoagulant activity and von Willebrand factor activity, as defined by ristocetin-induced platelet aggregation, was eluted in the void volume. Purified Factor VIII immediately lost about 30% of its procoagulant activity when dissolved in 0.25 M CaCl2, and when rechromatographed on 4% agarose in 0.25 M CaCl2, the protein peak and von Willebrand factor activity remained coincident in the void volume; however, most of the remaining procoagulant activity was eluted after the void volume. The elution position of Factor VIII procoagulant activity from 4% agarose in 0.25 M CaCl2, and hence its apparent molecular weight, varied with the protein concentration applied to the column; at low protein concentrations it was eluted close to the inner volume. Yet on Sephadex G-200 in 0.25 M CaCl2, the protein and procoagulant activity were eluted together in the void volume. These observations suggested that the Factor VIII procoagulant activity was not eluting according to size or shape, but was adsorbing to some extent to the agarose. Isolated activity peak material from the 0.25 M CaCl2 columns contained protein and had a typical ultraviolet spectrum. Even at high concentrations, the protein contained no thrombin, Factors IX, X, or Xa activity, or detectable phospholipid. In addition to Factor VIII procoagulant activity, which could be inactivated by a human antibody to Factor VIII, the activity peak protein also contained von Willebrand factor activity. Like native Factor VIII and the void volume protein, the activity peak contained protein that did not enter a sodium dodecyl sulfate 5% polyacrylamide gel in the absence of reducing reagent. After reduction of disulfide bonds, several subunits ranging from 195,000 to 30,000 daltons were observed. These results indicate that the protein in the shifted Factor VIII procoagulant activity peak is large and that its anomalous elution pattern from 4% agarose in 0.25 M CaCl2 results from interaction with the agarose. The Factor VIII-like properties of the activity peak protein and its electrophoretic pattern on sodium dodecyl sulfate gels suggest that it is a species of Factor VIII modified by proteolytic cleavage. These results allow an interpretation that is different from the recently proposed "carrier protein-small active subunit" hypotheses for the structure-function relationships of the Factor VIII molecule.
当纯化的抗血友病因子(因子VIII)在0.15 M NaCl或1.0 M NaCl中的4%琼脂糖上进行再层析时,一个单一的蛋白峰在空体积中被洗脱,该蛋白峰同时含有促凝血活性和血管性血友病因子活性(由瑞斯托霉素诱导的血小板聚集定义)。纯化的因子VIII溶解于0.25 M CaCl2时立即失去约30%的促凝血活性,当在0.25 M CaCl2中的4%琼脂糖上进行再层析时,蛋白峰和血管性血友病因子活性仍在空体积中重合;然而,大部分剩余的促凝血活性在空体积之后被洗脱。因子VIII促凝血活性从0.25 M CaCl2中的4%琼脂糖上的洗脱位置,以及因此其表观分子量,随加样到柱上的蛋白浓度而变化;在低蛋白浓度时,它在接近内体积处被洗脱。然而在0.25 M CaCl2中的葡聚糖凝胶G - 200上,蛋白和促凝血活性在空体积中一起被洗脱。这些观察结果表明,因子VIII促凝血活性不是按大小或形状洗脱,而是在一定程度上吸附到琼脂糖上。从0.25 M CaCl2柱上分离的活性峰物质含有蛋白且具有典型的紫外光谱。即使在高浓度时,该蛋白也不含凝血酶、因子IX、X或Xa活性,或可检测到的磷脂。除了可被人抗因子VIII抗体灭活的因子VIII促凝血活性外,活性峰蛋白还含有血管性血友病因子活性。与天然因子VIII和空体积蛋白一样,活性峰含有在没有还原剂时不进入十二烷基硫酸钠5%聚丙烯酰胺凝胶的蛋白。在二硫键还原后,观察到几个分子量范围从195,000到30,000道尔顿的亚基。这些结果表明,因子VIII促凝血活性峰中迁移的蛋白很大,其在0.25 M CaCl2中的4%琼脂糖上的异常洗脱模式是与琼脂糖相互作用的结果。活性峰蛋白的因子VIII样特性及其在十二烷基硫酸钠凝胶上的电泳图谱表明它是一种经蛋白水解裂解修饰的因子VIII。这些结果给出了一种与最近提出的关于因子VIII分子结构 - 功能关系的“载体蛋白 - 小活性亚基”假说不同的解释。